Metabolic health research
Obesity is an increasing problem. Our Metabolic Health Research (MHR) expertise group helps to reduce the burden of disease through preclinical research. We focus on metabolic diseases, such as type-2 diabetes and obesity. With research, we accelerate the development of new drugs, functional foods, diagnostics, and prevention.
Our MHR expertise group develops cellular and animal models to study mechanisms, interventions, and biomarkers in metabolic diseases, and the associated complications. In preclinical research, we apply the following models:
- Translational models, including unique, humanised transgenic mouse models.
- In vivo and in vitro fibrosis models, combined with histological, biochemical, molecular biological, cell biological, and immunological analysis methods.
We focus on improving research on the effectiveness and safety of interventions using drugs or food. We do this by increasing knowledge of disease processes and mechanisms, and we improve the translation to humans.
Knowledge and experience
We have extensive experience in the design and implementation of applied scientific research. In addition, we invest heavily in professional project management and work with quality systems. We deliver customised projects through the direct interaction of our MHR scientists with clients.
Metabolic disease and complications
The projects are characterised by a combination of knowledge and expertise in the field of metabolic health and metabolic disease, and the associated complications, such as:
- cardiovascular diseases
- hepatic steatosis
Within MHR, we work on projects with and for partners, such as:
- industrial biotechnology
- pharmaceutical industry
- food industry
- patient organisations
- public authorities
Our research provides new insights and possibilities for treating or preventing metabolic diseases. A few examples:
- A diet in which we alternate cholesterol-free food with ‘Western’ food containing a lot of cholesterol. This has a more or less similar effect on the prevention of cardiovascular disease and liver inflammation as a completely cholesterol-free diet.
- Metabolic stress, caused by being overweight, plays a more prominent role in the development of osteoarthritis than higher mechanical stress.
- A new statistical approach leads to a reduction in laboratory animal use.
Possibilities for visualising and analysing body fat in laboratory animals using non-invasive MRI.
Ivana BobeldijkFunction not known
Standplaats:Leiden - Sylviusweg
Telefoon:+31 88 866 16 25
LinkedIn:Ivana on LinkedIn
Looking for an expert?View all experts
Ancora Health develops personal diabetes plan with 360 methodology
With the help of TNO's knowledge of diabetic typing, Ancora Health wants to implement a diabetes lifestyle programme within healthcare.
MixMasters uses TNO phenotype test to offer personalised nutrition
TNO is helping MixMasters answer the question 'How can we personalise while remaining user-friendly?' Moreover, during their collaboration, the idea for a new concept was born: FoodiYou.
Personalised Health: Take it personal
TNO helps companies develop scientifically based personalised health applications. Knowledge is translated into applications by using a systems approach, and personalised health is put into practice. An example of this is the collaboration with Gabriele Ronnett of Johnson & Johnson Consumer Health Company.
Personalised Health: From science to market
Are you interested in developing personalised health in order to contribute to a healthier society? Get inspired by the experience of companies that already innovate with us. Watch this interactive webinar for the latest insights in personalised health: from science to market.
TNO publishes fully integreated Annual Report 2022
TNO's Annual Report 2022 is published. For the first time, it concerns a fully integrated annual report, in which sustainability is fully incorporated into the general annual report.